Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Anticipated emergency treatment of an acute attack of hereditary angioedema Clinical criteria: Treatment Phase: Initial Patient must have confirmed diagnosis of C1-esterase inhibitor deficiency, AND Patient must have been assessed to be at significant risk of an acute attack of hereditary angioedema, AND The condition must be assessed by a clinical immunologist; OR The condition must be assessed by a respiratory physician; OR The condition must be assessed by a specialist allergist; OR The condition must be assessed by a general physician experienced in the management of patients with hereditary angioedema. The name of the specialist consulted must be provided at the time of application for initial supply. The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application. Increased maximum quantities will be limited to 12 injections per authority prescription.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Icatibant is a selective competitive antagonist at the bradykinin type 2 (B2) receptor.”
“The terminal half-life (t1/2) is about 1-2 hours.”
“In vitro studies have confirmed that icatibant is not degraded by oxidative metabolic pathways and is not an inhibitor of major cytochrome P450 (CYP) isoenzymes (CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) and is not an inducer of CYP 1A2 and 3A4.”
Working under the parallel aged-care framework? Aged-care equivalent →